IRIDEX (NASDAQ:IRIX) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05, Fidelity Earnings reports. The business had revenue of $10.66 million during the quarter, compared to analyst estimates of $10.08 million. IRIDEX had a negative net margin of 26.02% and a negative return on equity of 39.42%.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Shares of NASDAQ IRIX traded down $0.22 during mid-day trading on Friday, reaching $1.93. The company had a trading volume of 128,600 shares, compared to its average volume of 43,958. The stock has a fifty day moving average of $1.88 and a two-hundred day moving average of $3.46. The company has a market capitalization of $29.30 million, a price-to-earnings ratio of -1.84 and a beta of 0.80. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.49 and a current ratio of 3.41. IRIDEX has a 12-month low of $1.50 and a 12-month high of $5.69.
A number of analysts have recently issued reports on IRIX shares. ValuEngine raised shares of IRIDEX from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of IRIDEX from a “buy” rating to a “hold” rating in a research report on Friday, November 1st.
IRIDEX Company Profile
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Further Reading: What is a resistance level?